Table 3 Sleeve gastrectomy versus adjustable gastric banding outcomes comparison.

From: Comparison of bariatric surgery and community weight management for idiopathic intracranial hypertension in a multicenter retrospective cohort study

Outcome

Follow-up duration

Sleeve gastrectomy

Adjustable gastric banding

Risk difference

Risk ratio

95% confidence interval

P-value

Papilledema

3 months

2.93%

3.61%

− 0.67%

0.813

0.396–1.669

0.5711

6 months

4.17%

3.47%

0.69%

1.2

0.613–2.35

0.5944

12 months

5.42%

5.87%

− 0.451

0.923

0.538–1.582

0.7709

24 months

7.00%

6.77%

0.23%

1.033

0.637–1.677

0.8944

Increased ICP

3 months

0

0

N/A

N/A

N/A

N/A

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.26%

0

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0

1

0.42–2.379

0.999

Headache

3 months

30.93%

28.22%

2.71%

1.096

0.894–1.343

0.377

6 months

37.04%

35.19%

1.85%

1.053

0.881–1.257

0.571

12 months

42.89%

41.76%

1.13%

1.027

0.881–1.198

0.7339

24 months

47.40%

46.73%

0.68%

1.014

0.882–1.167

0.84

Optic Atrophy

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.26%

0

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0

1

0.42–2.379

0.999

Blindness

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

3.39%

− 1.13%

0.667

0.303–1.468

0.3104

24 months

2.71%

4.29%

− 1.58%

0.632

0.31–1.285

0.2006

Pulsatile tinnitus

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

2.32%

− 2.32%

N/A

N/A

0.0015

12 months

2.26%

2.26%

0

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0

1

0.42–2.379

0.999

Abducent nerve palsy

3 months

0

2.26%

− 2.26%

N/A

N/A

0.0015

6 months

0

2.32%

− 2.32%

N/A

N/A

0.0015

12 months

0

2.26%

− 2.26%

N/A

N/A

0.0015

24 months

2.26%

2.26%

0

1

0.42–2.379

0.999

Diplopia

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.26%

0

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0

1

0.42–2.379

0.999

Refractory IIH

3 months

29.57%

27.09%

2.48%

1.092

0.885–1.346

0.41

6 months

35.88%

33.57%

2.32%

1.069

0.89–1.284

0.4749

12 months

41.54%

40.63%

0.90%

1.022

0.873–1.197

0.7847

24 months

46.05%

45.15%

0.90%

1.02

0.883–1.178

0.7873

Visual discomfort and visual field defects

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.94%

− 0.68%

0.769

0.341–1.736

0.5262

24 months

3.16%

3.61%

− 0.45%

0.875

0.432–1.771

0.7103

CSF leak

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

0.00%

2.32%

− 2.32%

N/A

N/A

0.0015

12 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

Therapeutic spinal puncture rate

3 months

2.26%

2.26%

0

1

0.42–2.379

0.999

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

CSF shunting rate

3 months

0

2.26%

− 2.26%

N/A

N/A

0.0015

6 months

2.32%

2.32%

0

1

0.42–2.378

0.999

12 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

24 months

2.26%

2.26%

0%

1

0.42–2.379

0.999

ONSF rate

3 months

0

0

N/A

N/A

N/A

N/A

6 months

0

0

N/A

N/A

N/A

N/A

12 months

0

0

N/A

N/A

N/A

N/A

24 months

0

0

N/A

N/A

N/A

N/A

Acetazolamide use

3 months

9.029

9.03%

0%

1

0.658–1.519

0.999

6 months

9.03%

8.80%

0.23%

1.026

0.67–1.572

0.905

12 months

12.42%

14.45%

− 2.03%

0.859

0.614–1.202

0.3752

24 months

13.77%

17.16%

− 3.39%

0.803

0.589–1.094

0.1634

Back to article page